Results from US Government-Sponsored Phase 1 Trial of VSV Vaccine Reported
?An early-stage clinical trial of an experimental Ebola vaccine conducted at the National Institutes of Health (NIH) and the Walter Reed Army Institute of Research (WRAIR) found that the vaccine, called VSV-ZEBOV, was safe and elicited robust antibody responses in all 40 of the healthy adults who received it. The most common side effects were injection site pain and transient fever that appeared and resolved within 12 to 36 hours after vaccination. A report describing preliminary results of the NIH-WRAIR study appears online today in The New England Journal of Medicine. The VSV-ZEBOV candidate is one of two experimental Ebola vaccines now being tested in the phase 2/3 PREVAIL clinical trial that is enrolling volunteers in Liberia.
“The ongoing Ebola outbreak in West Africa is unprecedented in scope and duration,” said Anthony S. Fauci, M.D., director of the National Institute of Allergy and Infectious Diseases (NIAID), part of the NIH. “The outbreak is slowly coming under control, thanks to extraordinary and multi-faceted efforts in the affected nations. However, there still are no licensed specific therapies or vaccines for Ebola. Until a safe and effective vaccine is available, the world will continue to be under-prepared for the next Ebola outbreak.”
Scientists at the Public Health Agency of Canada developed the candidate vaccine. It was licensed to NewLink Genetics Corp. of Ames, Iowa, a company collaborating with Merck & Co. Inc., of Kenilworth, New Jersey, which is responsible for advancing this vaccine towards regulatory approval. The investigational vaccine is based on a genetically modified and attenuated vesicular stomatitis virus (VSV), a virus that mainly affects cattle. In the investigational vaccine, a gene for a VSV protein is replaced with a gene segment from a key protein in the Zaire species of Ebola virus. The vaccine does not contain the whole Ebola virus and therefore cannot infect vaccinated persons with Ebola.
The new report summarizes results of the first 52 volunteers enrolled in the study: 26 at the NIH Clinical Center in Bethesda, Maryland, and 26 at the WRAIR clinic in Silver Spring, Maryland. Six volunteers at each site received a placebo injection of saline solution, and the remaining 40 received the experimental vaccine at either one of two different dosages (2 x107 or 3 x106 in 20 volunteers at each site). The NIH trial was led by NIAID investigators Richard T. Davey, Jr., M.D., and John H. Beigel, M.D., while Jason A. Regules, M.D., and Stephen J. Thomas, M.D., headed the trial at WRAIR.
The candidate vaccine’s ability to stimulate immune responses was assessed by sampling the volunteers’ blood at multiple time points following injection. (The blood sampling schedule differed between the two trial sites.) Of those volunteers tested at 14 days after injection, 93 percent (26 out of 28) of whose who had received vaccine developed antibodies against Zaire species of Ebola virus. Antibodies were detected in the remaining 14 volunteers who had received vaccine by 28 days after injection. Antibody responses were approximately three-fold greater in those who received the higher vaccine dose. This information was available to the designers of the PREVAIL trial and was used to guide the decision to use VSV-ZEBOV at the higher dosage level in that trial.
“The prompt, dose-dependent production of high levels of antibodies following a single injection and the overall favorable safety profile of this vaccine make VSV-ZEBOV a promising candidate that might be particularly useful in outbreak interventions,” said Dr. Davey.
The Latest on: Ebola Vaccine
via Google News
The Latest on: Ebola Vaccine
- Different outbreak, same strategy: Inside Novavax's plans for a China coronavirus vaccineon January 24, 2020 at 11:33 am
Novavax's China coronavirus vaccine development should come as no surprise — the Gaithersburg biotech made similar moves for Zika, Ebola and swine flu. But what's the end game this time?
- Wistar joins effort to expedite Coronavirus vaccine development for outbreak in Chinaon January 23, 2020 at 11:25 am
CEPI will fund nearly $9 million to support pre-clinical and clinical research for a vaccine advanced ... Prior work by this team includes development of vaccines for Ebola, Zika and MERS, another ...
- A coalition backed by Bill Gates is funding biotechs that are scrambling to develop vaccines for the deadly Wuhan coronaviruson January 23, 2020 at 9:45 am
Biotechs like Moderna and Inovio are working to develop a vaccine for the new virus, with support from the Coalition for Epidemic Preparedness Innovations.
- A vaccine for Wuhan coronavirus could take years to develop, based on our experience trying to fight Zika and Ebolaon January 23, 2020 at 6:25 am
The Wuhan coronavirus has now infected more than 630 people and spread to 9 countries. At least 18 people have died.
- Despite outbreak, Ebola treatment and vaccine represent ‘resounding scientific success’on January 16, 2020 at 2:30 pm
I have — also the development of a molecule that can treat Ebola patients. The treatment was a breakthrough. But with a third of the patients still dying, the vaccine was critical, a way to protect ...
- Emergex raises more than US$11 million in a Series…on January 9, 2020 at 3:22 am
Emergex develops set-point vaccines to prevent some of the world’s most immediate and virulent diseases such as Zika, Dengue Fever, Ebola and pandemic Flu ... vaccine towards the clinic Abingdon, UK, ...
- Ebola vaccine found safe for children, adults in Africaon January 8, 2020 at 4:00 pm
Washington D.C. [U.S.A], Oct. 9 : The worst Ebola outbreak ended in ... promising data as a group of researchers have found an Ebola vaccine is safe for children as well as adults and produces ...
- NewLink Genetics Announces European Commission Grant of Conditional Marketing Approval for Ebola Vaccine V920 (ERVEBO®)on January 6, 2020 at 5:01 am
Before it's here, it's on the Bloomberg Terminal.
- FDA’s approval of Ebola vaccine will be felt around the worldon December 20, 2019 at 2:30 pm
Stockpiling such a vaccine is crucial to world safety as Ebola has long been a potential bioterrorism threat, especially after 9/11. In the world of theoretical biological warfare, where the virus ...
- Merck Announces FDA Approval for ERVEBO® (Ebola Zaire Vaccine, Live)on December 20, 2019 at 5:13 am
“Having an Ebola vaccine approved by the FDA is a significant ... with all but one study reporting rash in
via Bing News